Core Insights - Kaisi China announced the upgrade of the "Marco Polo Program" to version 3.0 at the 8th China International Import Expo, emphasizing its commitment to enhancing medical accessibility and advocating for healthcare equity [1][9] - The company aims to deepen collaborations with various partners, including JD Health and the China Rare Disease Alliance, to expand its ecosystem and improve patient care [1][7] Group 1: Strategic Collaborations - Kaisi signed a strategic cooperation agreement with JD Health, allowing the full line of respiratory products to be available on JD Health, focusing on disease education, online consultations, and chronic disease management [3] - Kaisi and Shangyao Cloud Health announced an upgraded strategic partnership to enhance outpatient services through "Yiyao Pharmacy," providing comprehensive health management for respiratory diseases [5] - A memorandum of cooperation was signed with the China Rare Disease Alliance to improve rare disease management and establish standardized treatment systems [7] Group 2: Product Innovations and Market Expansion - Kaisi showcased its innovative respiratory product, the inhalation powder aerosol, at the expo, aiming to provide new treatment options for asthma patients in China [10] - The company introduced nine innovative rare disease drugs, including FILSUVEZ®, which is the first approved treatment for certain genetic skin disorders, highlighting its commitment to addressing unmet medical needs [10] - Kaisi's "CARE" specialty treatment area has already helped 1.38 million premature infants in China, demonstrating its impact on public health [9] Group 3: Commitment to Healthcare Equity - Kaisi emphasizes the importance of medical equity and has initiated various programs to enhance awareness and treatment options for premature infants and respiratory diseases [9][10] - The company aims to leverage the "spillover effect" of the Import Expo to accelerate the introduction of innovative products and improve accessibility for patients [11]

Core Viewpoint - Kaisi China announced the upgrade of the "Marco Polo Program" to version 3.0 during the 8th China International Import Expo, marking a significant milestone in Sino-Italian cooperation and showcasing innovative pharmaceutical products [1] Group 1: Strategic Partnerships - Kaisi China signed a strategic cooperation agreement with JD Health, enabling the full line of respiratory products to be available on the platform, focusing on disease education, online consultations, and smart chronic disease management [2] - Kaisi China upgraded its strategic cooperation with Shanghai Pharmaceutical Cloud Health, allowing its respiratory health products to be integrated into "Yiyao Pharmacy" for comprehensive outpatient services [2] - A memorandum of cooperation was signed with the China Rare Disease Alliance to enhance rare disease management and establish standardized treatment systems [2] Group 2: Product Innovations - In the "CARE" specialty treatment area, Kaisi China showcased its key products for premature infants, including porcine lung surfactant injection and caffeine citrate injection [3] - The "AIR" respiratory health sector introduced a new inhalation powder for asthma patients, providing a new treatment option [3] - Kaisi China presented nine innovative rare disease drugs at the expo, targeting eleven rare diseases, with some being the only treatment options available [3] - The first drug approved for treating wounds related to certain genetic skin disorders was highlighted, benefiting patients in China [3] Group 3: Academic and Professional Development - Kaisi China launched the "Everest Project" to promote high-level academic exchanges and cooperation among top respiratory experts, enhancing medical education and patient management [3]